The “Gender Factor” in Wearing-Off among Patients with Parkinson’s Disease: A Post Hoc Analysis of DEEP Study
Table 2
Gender differences on clinical aspects of DEEP population: women versus men.
Women
Men
Disease duration, mean ± SD
0.389
<5 years, (%)
66 (28.0)
119 (31.2)
>5 years, (%)
170 (72.0)
262 (68.8)
H&Y, (%)#
0.291
2
134 (56.8)
233 (61.1)
2.5
101 (42.8)
148 (38.6)
UPDRS total score, mean ± SD
36.2 ± 17.7
38.1 ± 17.4
0.223
Part I
2.3 ± 2.0
2.1 ± 1.9
0.287
Part II
11.1 ± 6.4
11.3 ± 6.0
0.621
Part III
23.0 ± 11.6
24.6 ± 11.8
0.129
PD subtypes, (%
0.006
TD
62 (26.3)
142 (37.3)
PIGD
120 (50.8)
172 (45.1)
0.0149
IND
29 (12.3)
28 (7.3)
0.0041
MMSE, mean ± SD
28.1 ± 1.67
28.2 ± 1.62
0.306
Anti-Parkinson drugs classes, (%)
0.4457
LD monotherapy
29 (12.3)
35 (9.2)
DA monotherapy
11 (4.7)
15 (3.9)
LD + DA
152 (64.4)
234 (61.4)
MAOIs
84 (35.6)
157 (41.2)
COMT inhibitors
79 (33.5)
132 (34.6)
LEDD, mg mean ± SD
844.2 ± 679.0
874.4 ± 749.1
0.622
Diagnosis of WO by neurologists, (%)
146 (61.9)
205 (53.8)
0.0495
<5 years disease duration
21 (31.8)
38 (31.9)
0.987
>5 years disease duration
125 (73.5)
167 (63.7)
0.034
Diagnosis of WO by WOQ-19, (%)
171 (72.5)
244 (64.0)
0.034
<5 years disease duration
37 (56.1)
57 (47.9)
0.2875
>5 years disease duration
134 (78.8)
187 (71.4)
0.0834
PDQ-8, mean ± SD
31.3 ± 18.4
27.7 ± 19.1
0.023
SD: standard deviation; H&Y: Hoehn and Yahr staging; UPDRS: unified Parkinson’s disease rating scale; PD: Parkinson's disease; TD: tremor dominant; PIGD: postural instability and gait difficulties; IND: intermediate; MMSE: mini-mental state examination; LD: levodopa; DA: dopamine-agonist; MAOIs: monoamine oxidase B inhibitors; COMT: catechol-O-methyltransferase; LEDD: levodopa equivalent daily dose; WO: wearing-off; WOQ-19: 19-item wearing-off questionnaire; PDQ-8: 8-item Parkinson's disease questionnaire. PD subtypes could not be calculated for 39 males and 25 females. Paired post hoc Chi-squares take TD as reference.
#Missing data for <10 patients/variable.
